- Conditions
- Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer
- Interventions
- IDRX-42
- Drug
- Lead sponsor
- IDRX, Inc., a wholly owned subsidiary of GSK, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 8
- States / cities
- Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 283
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Interventions
- mutation analysis, pharmacological study, dynamic contrast-enhanced magnetic resonance imaging, sunitinib malate, immunohistochemistry staining method, laboratory biomarker analysis
- Genetic · Other · Procedure + 1 more
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Neoplasms
- Interventions
- exemestane, sunitinib malate
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- 3rd Line GIST
- Interventions
- ST571 + BYL719
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Renal Cell Carcinoma
- Interventions
- Sunitinib, Nephrectomy
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2026
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- Sunitinib, Regorafenib
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, Sunitinib, EBXRT
- Drug · Radiation
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • New Brunswick, New Jersey • Durham, North Carolina
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- GB-102, Aflibercept
- Drug
- Lead sponsor
- Graybug Vision
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 8
- States / cities
- Gilbert, Arizona • Beverly Hills, California • Indianapolis, Indiana + 5 more
- Conditions
- Sarcoma, Soft Tissue
- Interventions
- Sunitinib
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Solid Tumors
- Interventions
- Dasatinib, Erlotinib, Lapatinib, Lenalidomide, Sorafenib, Sunitinib, Valproic Acid
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Interventions
- sunitinib malate
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Bicalutamide in combination with Sunitinib
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Inflammatory Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- sunitinib malate, paclitaxel, doxorubicin hydrochloride, cyclophosphamide, filgrastim, therapeutic conventional surgery, laboratory biomarker analysis, flow cytometry
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- Not listed
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 7
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Boise, Idaho + 3 more
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Sunitinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 11
- States / cities
- Duarte, California • Pasadena, California • San Francisco, California + 6 more
- Conditions
- Cancer
- Interventions
- sunitinib malate (Sutent), radiotherapy
- Drug · Procedure
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neoplasms
- Interventions
- carboplatin + SU011248 (sunitinib) + paclitaxel
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • Philadelphia, Pennsylvania • Houston, Texas + 1 more
- Conditions
- Lung Cancer
- Interventions
- Sunitinib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Interventions
- Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Idarubicin, Idelalisib, In Vitro Kinase Inhibitor Assay, Leucovorin Calcium, Methotrexate, Methylprednisolone Sodium Succinate, Ponatinib Hydrochloride, Rituximab, Ruxolitinib Phosphate, Sorafenib Tosylate, Sunitinib Malate, Vincristine Sulfate
- Drug · Device · Biological
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- GIST
- Interventions
- BIIB021
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 3
- States / cities
- Encinitas, California • Santa Monica, California • San Antonio, Texas
- Conditions
- Renal Cell Carcinoma
- Interventions
- Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Bevacizumab, Sunitinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 25
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 19 more
- Conditions
- Renal Cell Cancer, Kidney Cancer
- Interventions
- Sunitinib Malate
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Colorectal Neoplasms, Neoplasms
- Interventions
- sunitinib + FOLFOX
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Nashville, Tennessee • Dallas, Texas
- Conditions
- Gastrointestinal Stromal Tumor
- Interventions
- Placebo, SU011248
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 27
- States / cities
- Duarte, California • Los Angeles, California • Pasadena, California + 20 more
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- RAD001, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 31
- States / cities
- Fayetteville, Arkansas • Duarte, California • Sacramento, California + 27 more